Literature DB >> 12892387

Prophylaxis of the antiphospholipid syndrome: a consensus report.

D Alarcón-Segovia1, M C Boffa, W Branch, R Cervera, A Gharavi, M Khamashta, Y Shoenfeld, W Wilson, R Roubey.   

Abstract

Hypothetical circumstances that may require prophylaxis for a potential antiphospholipid syndrome (primary prophylaxis), or in some instances when there already had been some manifestations ofthe syndrome (secondary prophylaxis), were presented to a panel of experts for their consideration on potential prophylactic intervention. These were subsequently presented to the participants in the First International Consensus on Treatment of the Antiphospholipid Syndrome. In most instances there was consensus in adding low dose aspirin, an exception being aspirin allergy when other antiaggregants could be used in nonpregnant subjects. General measures to prevent thrombosis and other vasoprotective actions should also be provided. Higher risk of fetal loss or thrombosis called for anticoagulation with coumadin in nonpregnant subjects or subcutaneous low molecular weight heparin in pregnant ones. When indicated, prophylaxis of the antiphospholipid syndrome should be provided in systemic lupus erythematosus patients who are being treated for their disease. In no instance should corticosteroids or immunosuppresants be given as prophylactic of an antiphospholipid syndrome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12892387     DOI: 10.1191/0961203303lu388oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  14 in total

Review 1.  Treatment of the antiphospholipid antibody syndrome.

Authors:  Christopher Wu; Kenneth Kalunian
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

2.  [Recurrent thromboembolisms despite full anticoagulation in a patient with antiphospholipid syndrome].

Authors:  S Wernicke; K Selleng; S B Felix; A Greinacher; F Hammer
Journal:  Internist (Berl)       Date:  2017-07       Impact factor: 0.743

3.  Antiphospholipid antibodies and sub-clinical atherosclerosis in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort.

Authors:  Darcy S Majka; Kiang Liu; Richard M Pope; Elizabeth W Karlson; Thanh-Huyen T Vu; Marius Teodorescu; Rowland W Chang
Journal:  Inflamm Res       Date:  2013-10       Impact factor: 4.575

Review 4.  Neurologic manifestations of the antiphospholipid syndrome: integrating molecular and clinical lessons.

Authors:  Eyal Muscal; Robin L Brey
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

5.  Primary thrombosis prevention in aPL-positive patients.

Authors:  Kathleen M O'Neil
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

Review 6.  Pediatric antiphospholipid syndrome.

Authors:  Cassyanne L Aguiar; Arzu Soybilgic; Tadej Avcin; Barry L Myones
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

7.  Clinical outcomes of childhood lupus nephritis: a single center's experience.

Authors:  Byong Sop Lee; Hee Yeon Cho; Eo Jin Kim; Hee Gyung Kang; Il Soo Ha; Hae Il Cheong; Joong Gon Kim; Hyun Soon Lee; Yong Choi
Journal:  Pediatr Nephrol       Date:  2006-11-28       Impact factor: 3.714

8.  Lupus nephritis and Raynaud's phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies.

Authors:  Kittiwan Choojitarom; Orawan Verasertniyom; Kitti Totemchokchyakarn; Kanokrat Nantiruj; Vasant Sumethkul; Suchela Janwityanujit
Journal:  Clin Rheumatol       Date:  2007-09-02       Impact factor: 2.980

9.  Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up.

Authors:  Tunde Tarr; Gabriella Lakos; Harjit Pal Bhattoa; Pal Soltesz; Yehuda Shoenfeld; Gyula Szegedi; Emese Kiss
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

10.  POTS and Antiphospholipid Syndrome: An Unlikely Association.

Authors:  Kalvin Zee; Shakaib Qureshi
Journal:  Case Rep Rheumatol       Date:  2021-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.